603231 索宝蛋白
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)3.76810.98922.54418.74430.818
总资产报酬率 ROA (%)3.3749.02815.85414.34425.952
投入资产回报率 ROIC (%)3.63310.22319.65316.90229.381

边际利润分析
销售毛利率 (%)11.73613.64813.26613.99814.400
营业利润率 (%)11.14810.52610.2509.2419.372
息税前利润/营业总收入 (%)9.71810.1169.8359.34910.024
净利润/营业总收入 (%)9.1718.6039.0997.8147.645

收益指标分析
经营活动净收益/利润总额(%)73.54195.37798.452107.17791.457
价值变动净收益/利润总额(%)7.1420.012-0.241-0.1766.698
营业外收支净额/利润总额(%)-1.915-4.157-0.249-2.826-0.233

偿债能力分析
流动比率 (X)7.9036.3251.5901.6633.288
速动比率 (X)6.3755.4110.8381.0032.189
资产负债率 (%)9.28711.53929.89729.41415.789
带息债务/全部投入资本 (%)1.0074.0399.64414.0474.646
股东权益/带息债务 (%)9,709.4232,355.095915.871611.3812,051.874
股东权益/负债合计 (%)976.797766.645234.485239.975533.337
利息保障倍数 (X)-7.960976.643-25.25825.84314.871

营运能力分析
应收账款周转天数 (天)38.78733.50226.49024.16625.836
存货周转天数 (天)61.66454.72548.61942.18142.980